Table of Content
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF GLOBAL MOLECULAR CYTOGENETIC MARKET
1.4 CURRENCY AND PRICING
1.5 LIMITATION
1.6 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 KEY TAKEAWAYS
2.2 ARRIVING AT THE GLOBAL XX SIZE
2.2.1 VENDOR POSITIONING GRID
2.2.2 TECHNOLOGY LIFE LINE CURVE
2.2.3 TRIPOD DATA VALIDATION MODEL
2.2.4 MARKET GUIDE
2.2.5 MULTIVARIATE MODELLING
2.2.6 TOP TO BOTTOM ANALYSIS
2.2.7 CHALLENGE MATRIX
2.2.8 APPLICATION COVERAGE GRID
2.2.9 STANDARDS OF MEASUREMENT
2.2.10 VENDOR SHARE ANALYSIS
2.2.11 DATA POINTS FROM KEY PRIMARY INTERVIEWS
2.2.12 DATA POINTS FROM KEY SECONDARY DATABASES
2.3 GLOBAL MOLECULAR CYTOGENETIC MARKET: RESEARCH SNAPSHOT
2.4 ASSUMPTIONS
3 MARKET OVERVIEW
3.1 DRIVERS
3.2 RESTRAINTS
3.3 OPPORTUNITIES
3.4 CHALLENGES
4 EXECUTIVE SUMMARY
5 PREMIUM INSIGHTS
5.1 PESTEL ANALYSIS
5.2 PORTER’S FIVE FORCES MODEL
6 INDUSTRY INSIGHTS
6.1 MICRO AND MACRO ECONOMIC FACTORS
6.2 PENETRATION AND GROWTH PROSPECT MAPPING
6.3 KEY PRICING STRATEGIES
6.4 INTERVIEWS WITH SPECIALIST
6.5 ANALYIS AND RECOMMENDATION
7 INTELLECTUAL PROPERTY (IP) PORTFOLIO
7.1 PATENT QUALITY AND STRENGTH
7.2 PATENT FAMILIES
7.3 LICENSING AND COLLABORATIONS
7.4 COMPETITIVE LANDSCAPE
7.5 IP STRATEGY AND MANAGEMENT
7.6 OTHER
8 COST ANALYSIS BREAKDOWN
9 TECHNONLOGY ROADMAP
10 INNOVATION TRACKER AND STRATEGIC ANALYSIS
10.1 MAJOR DEALS AND STRATEGIC ALLIANCES ANALYSIS
10.1.1 JOINT VENTURES
10.1.2 MERGERS AND ACQUISITIONS
10.1.3 LICENSING AND PARTNERSHIP
10.1.4 TECHNOLOGY COLLABORATIONS
10.1.5 STRATEGIC DIVESTMENTS
10.2 NUMBER OF PRODUCTS IN DEVELOPMENT
10.3 STAGE OF DEVELOPMENT
10.4 TIMELINES AND MILESTONES
10.5 INNOVATION STRATEGIES AND METHODOLOGIES
10.6 RISK ASSESSMENT AND MITIGATION
10.7 FUTURE OUTLOOK
11 REGULATORY COMPLIANCE
11.1 REGULATORY AUTHORITIES
11.2 REGULATORY CLASSIFICATIONS
11.2.1 CLASS I
11.2.2 CLASS II
11.2.3 CLASS III
11.3 REGULATORY SUBMISSIONS
11.4 INTERNATIONAL HARMONIZATION
11.5 COMPLIANCE AND QUALITY MANAGEMENT SYSTEMS
11.6 REGULATORY CHALLENGES AND STRATEGIES
12 REIMBURSEMENT FRAMEWORK
13 OPPUTUNITY MAP ANALYSIS
14 INSTALLED BASE DATA
15 VALUE CHAIN ANALYSIS
16 HEALTHCARE ECONOMY
16.1 HEALTHCARE EXPENDITURE
16.2 CAPITAL EXPENDITURE
16.3 CAPEX TRENDS
16.4 CAPEX ALLOCATION
16.5 FUNDING SOURCES
16.6 INDUSTRY BENCHMARKS
16.7 GDP RATION IN OVERALL GDP
16.8 HEALTHCARE SYSTEM STRUCTURE
16.9 GOVERNMENT POLICIES
16.1 ECONOMIC DEVELOPMENT
17 GLOBAL MOLECULAR CYTOGENETIC MARKET, BY PRODUCT
17.1 OVERVIEW
17.2 INSTRUMENTS
17.2.1 BY PRODUCT
17.2.1.1. AUTOMATED
17.2.1.1.1. MARKET VALUE (USD MILLION)
17.2.1.1.2. MARKET VOLUME (UNITS)
17.2.1.1.3. AVERAGE SELLING PRICE (USD)
17.2.1.2. SEMIAUTOMATED
17.2.1.2.1. MARKET VALUE (USD MILLION)
17.2.1.2.2. MARKET VOLUME (UNITS)
17.2.1.2.3. AVERAGE SELLING PRICE (USD)
17.2.1.3. MANUAL
17.2.1.3.1. MARKET VALUE (USD MILLION)
17.2.1.3.2. MARKET VOLUME (UNITS)
17.2.1.3.3. AVERAGE SELLING PRICE (USD)
17.2.2 BY TYPE
17.2.2.1. HIGH SEQUENCING
17.2.2.1.1. MARKET VALUE (USD MILLION)
17.2.2.1.2. MARKET VOLUME (UNITS)
17.2.2.1.3. AVERAGE SELLING PRICE (USD)
17.2.2.2. LOW SEQUENCING
17.2.2.2.1. MARKET VALUE (USD MILLION)
17.2.2.2.2. MARKET VOLUME (UNITS)
17.2.2.2.3. AVERAGE SELLING PRICE (USD)
17.2.3 BY MODALITY
17.2.3.1. STANDALONE
17.2.3.1.1. MARKET VALUE (USD MILLION)
17.2.3.1.2. MARKET VOLUME (UNITS)
17.2.3.1.3. AVERAGE SELLING PRICE (USD)
17.2.3.2. PORTABLES
17.2.3.2.1. MARKET VALUE (USD MILLION)
17.2.3.2.2. MARKET VOLUME (UNITS)
17.2.3.2.3. AVERAGE SELLING PRICE (USD)
17.2.3.3. BENCHTOP
17.2.3.3.1. MARKET VALUE (USD MILLION)
17.2.3.3.2. MARKET VOLUME (UNITS)
17.2.3.3.3. AVERAGE SELLING PRICE (USD)
17.3 KITS, REAGENTS AND CONSUMABLES
17.3.1 PROBES
17.3.1.1. LOCUS SPECIFIC PROBES
17.3.1.1.1. MARKET VALUE (USD MILLION)
17.3.1.1.2. MARKET VOLUME (UNITS)
17.3.1.1.3. AVERAGE SELLING PRICE (USD)
17.3.1.2. REPETITIVE PROBES
17.3.1.2.1. MARKET VALUE (USD MILLION)
17.3.1.2.2. MARKET VOLUME (UNITS)
17.3.1.2.3. AVERAGE SELLING PRICE (USD)
17.3.1.3. PARTIAL CHROMOSOME PAINTS
17.3.1.3.1. MARKET VALUE (USD MILLION)
17.3.1.3.2. MARKET VOLUME (UNITS)
17.3.1.3.3. AVERAGE SELLING PRICE (USD)
17.3.1.4. WHOLE CHROMOSOME PAINTS
17.3.1.4.1. MARKET VALUE (USD MILLION)
17.3.1.4.2. MARKET VOLUME (UNITS)
17.3.1.4.3. AVERAGE SELLING PRICE (USD)
17.3.1.5. WHOLE GENOME PROBES
17.3.1.5.1. MARKET VALUE (USD MILLION)
17.3.1.5.2. MARKET VOLUME (UNITS)
17.3.1.5.3. AVERAGE SELLING PRICE (USD)
17.3.1.6. OTHERS
17.3.2 HYBRIDIZATION BUFFER
17.3.2.1. MARKET VALUE (USD MILLION)
17.3.2.2. MARKET VOLUME (UNITS)
17.3.2.3. AVERAGE SELLING PRICE (USD)
17.3.3 MOUNTING MEDIUM
17.3.3.1. MARKET VALUE (USD MILLION)
17.3.3.2. MARKET VOLUME (UNITS)
17.3.3.3. AVERAGE SELLING PRICE (USD)
17.3.4 OTHERS
17.4 SOFTWARE AND SERVICES
18 GLOBAL MOLECULAR CYTOGENETIC MARKET, BY TECHNIQUE
18.1 OVERVIEW
18.2 FLUORESCENT IN SITU HYBRIDIZATION (FISH)
18.3 COMPARATIVE GENOMIC HYBRIDIZATION (CGH)
18.4 PRIMED IN SITU LABELLING (PRINS)
18.5 SPECTRAL KARYOTYPING(SKY)
18.6 MULTIPLEX-FLUORESCENT IN SITU HYBRIDIZATION (M-FISH) TECHNIQUE
18.7 KARYOTYPING
18.8 BANDING TECHNIQUES
18.8.1 G BANDING
18.8.2 Q BANDING
18.8.3 R BANDING
18.8.4 C BANDING
18.8.5 T BANDING
18.8.6 OTHERS
18.9 OTHERS
19 GLOBAL MOLECULAR CYTOGENETIC MARKET, BY APPLICATION
19.1 OVERVIEW
19.2 ONCOLOGY
19.2.1 BREAST CARCINOMAS
19.2.2 PULMONARY ADENOCARCINOMAS
19.2.3 HEMATOLOGICAL MALIGNANCIES
19.2.4 OTHERS
19.3 GENETIC DISORDERS
19.3.1 DOWN SYNDROME
19.3.2 TURNER SYNDROME
19.3.3 OTHERS
19.4 BRAIN DISORDERS
19.5 OTHERS
20 GLOBAL MOLECULAR CYTOGENETIC MARKET, BY USAGE
20.1 OVERVIEW
20.2 DIAGNOSIS
20.2.1 FLUORESCENT IN SITU HYBRIDIZATION (FISH)
20.2.2 COMPARATIVE GENOMIC HYBRIDIZATION (CGH)
20.2.3 PRIMED IN SITU LABELLING (PRINS)
20.2.4 SPECTRAL KARYOTYPING(SKY)
20.2.5 MULTIPLEX-FLUORESCENT IN SITU HYBRIDIZATION (M-FISH) TECHNIQUE
20.2.6 KARYOTYPING
20.2.7 BANDING TECHNIQUES
20.2.8 OTHERS
20.3 PROGNOSIS
20.3.1 FLUORESCENT IN SITU HYBRIDIZATION (FISH)
20.3.2 COMPARATIVE GENOMIC HYBRIDIZATION (CGH)
20.3.3 PRIMED IN SITU LABELLING (PRINS)
20.3.4 SPECTRAL KARYOTYPING(SKY)
20.3.5 MULTIPLEX-FLUORESCENT IN SITU HYBRIDIZATION (M-FISH) TECHNIQUE
20.3.6 KARYOTYPING
20.3.7 BANDING TECHNIQUES
20.3.8 OTHERS
20.4 THERAPEUTICS
20.4.1 FLUORESCENT IN SITU HYBRIDIZATION (FISH)
20.4.2 COMPARATIVE GENOMIC HYBRIDIZATION (CGH)
20.4.3 PRIMED IN SITU LABELLING (PRINS)
20.4.4 SPECTRAL KARYOTYPING(SKY)
20.4.5 MULTIPLEX-FLUORESCENT IN SITU HYBRIDIZATION (M-FISH) TECHNIQUE
20.4.6 KARYOTYPING
20.4.7 BANDING TECHNIQUES
20.4.8 OTHERS
21 GLOBAL MOLECULAR CYTOGENETIC MARKET, BY END USER
21.1 OVERVIEW
21.2 PHARMACEUTICALS AND BIOTECHNOLOGY COMPANIES
21.2.1 SMALL ENTERPRISE
21.2.2 MEDIUM ENTERPRISE
21.2.3 LARGE ENTERPRISE
21.3 CLINICAL AND DIAGNOSTIC LABORATORIES
21.4 ACADEMIC INSTITUTES
21.5 OTHERS
22 GLOBAL MOLECULAR CYTOGENETIC MARKET, BY DISTRIBUTION CHANNEL
22.1 OVERVIEW
22.2 DIRECT TENDERS
22.3 RETAIL SALES
22.4 OTHERS
23 GLOBAL MOLECULAR CYTOGENETIC MARKET, SWOT AND DBMR ANALYSIS
24 GLOBAL MOLECULAR CYTOGENETIC MARKET, COMPANY LANDSCAPE
24.1 COMPANY SHARE ANALYSIS: GLOBAL
24.2 COMPANY SHARE ANALYSIS: NORTH AMERICA
24.3 COMPANY SHARE ANALYSIS: EUROPE
24.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC
24.5 MERGERS & ACQUISITIONS
24.6 NEW PRODUCT DEVELOPMENT & APPROVALS
24.7 EXPANSIONS
24.8 REGULATORY CHANGES
24.9 PARTNERSHIP AND OTHER STRATEGIC DEVELOPMENTS
25 GLOBAL MOLECULAR CYTOGENETIC MARKET, BY REGION
25.1 GLOBAL MOLECULAR CYTOGENETIC MARKET, (ALL SEGMENTATION PROVIDED ABOVE IS REPRESENTED IN THIS CHAPTER BY COUNTRY)
25.2 NORTH AMERICA
25.2.1 U.S.
25.2.2 CANADA
25.2.3 MEXICO
25.3 EUROPE
25.3.1 GERMANY
25.3.2 U.K.
25.3.3 ITALY
25.3.4 FRANCE
25.3.5 SPAIN
25.3.6 RUSSIA
25.3.7 SWITZERLAND
25.3.8 TURKEY
25.3.9 BELGIUM
25.3.10 NETHERLANDS
25.3.11 DENMARK
25.3.12 SWEDEN
25.3.13 POLAND
25.3.14 NORWAY
25.3.15 FINLAND
25.3.16 REST OF EUROPE
25.4 ASIA-PACIFIC
25.4.1 JAPAN
25.4.2 CHINA
25.4.3 SOUTH KOREA
25.4.4 INDIA
25.4.5 SINGAPORE
25.4.6 THAILAND
25.4.7 INDONESIA
25.4.8 MALAYSIA
25.4.9 PHILIPPINES
25.4.10 AUSTRALIA
25.4.11 NEW ZEALAND
25.4.12 VIETNAM
25.4.13 TAIWAN
25.4.14 REST OF ASIA-PACIFIC
25.5 SOUTH AMERICA
25.5.1 BRAZIL
25.5.2 ARGENTINA
25.5.3 REST OF SOUTH AMERICA
25.6 MIDDLE EAST AND AFRICA
25.6.1 SOUTH AFRICA
25.6.2 EGYPT
25.6.3 BAHRAIN
25.6.4 UNITED ARAB EMIRATES
25.6.5 KUWAIT
25.6.6 OMAN
25.6.7 QATAR
25.6.8 SAUDI ARABIA
25.6.9 REST OF MEA
25.7 KEY PRIMARY INSIGHTS: BY MAJOR COUNTRIES
26 GLOBAL MOLECULAR CYTOGENETIC MARKET, COMPANY PROFILE
26.1 ILLUMINA INC
26.1.1 COMPANY OVERVIEW
26.1.2 REVENUE ANALYSIS
26.1.3 GEOGRAPHIC PRESENCE
26.1.4 PRODUCT PORTFOLIO
26.1.5 RECENT DEVELOPMENTS
26.2 PERKINELMER INC.
26.2.1 COMPANY OVERVIEW
26.2.2 REVENUE ANALYSIS
26.2.3 GEOGRAPHIC PRESENCE
26.2.4 PRODUCT PORTFOLIO
26.2.5 RECENT DEVELOPMENTS
26.3 MICROPTIC
26.3.1 COMPANY OVERVIEW
26.3.2 REVENUE ANALYSIS
26.3.3 GEOGRAPHIC PRESENCE
26.3.4 PRODUCT PORTFOLIO
26.3.5 RECENT DEVELOPMENTS
26.4 LEICA BIOSYSTEMS NUSSLOCH GMBH
26.4.1 COMPANY OVERVIEW
26.4.2 REVENUE ANALYSIS
26.4.3 GEOGRAPHIC PRESENCE
26.4.4 PRODUCT PORTFOLIO
26.4.5 RECENT DEVELOPMENTS
26.5 METASYSTEMS PROBES
26.5.1 COMPANY OVERVIEW
26.5.2 REVENUE ANALYSIS
26.5.3 GEOGRAPHIC PRESENCE
26.5.4 PRODUCT PORTFOLIO
26.5.5 RECENT DEVELOPMENTS
26.6 EXCILONE
26.6.1 COMPANY OVERVIEW
26.6.2 REVENUE ANALYSIS
26.6.3 GEOGRAPHIC PRESENCE
26.6.4 PRODUCT PORTFOLIO
26.6.5 RECENT DEVELOPMENTS
26.7 BIOGENEX
26.7.1 COMPANY OVERVIEW
26.7.2 REVENUE ANALYSIS
26.7.3 GEOGRAPHIC PRESENCE
26.7.4 PRODUCT PORTFOLIO
26.7.5 RECENT DEVELOPMENTS
26.8 F. HOFFMANN-LA ROCHE LTD
26.8.1 COMPANY OVERVIEW
26.8.2 REVENUE ANALYSIS
26.8.3 GEOGRAPHIC PRESENCE
26.8.4 PRODUCT PORTFOLIO
26.8.5 RECENT DEVELOPMENTS
26.9 CYTOGNOMIX
26.9.1 COMPANY OVERVIEW
26.9.2 REVENUE ANALYSIS
26.9.3 GEOGRAPHIC PRESENCE
26.9.4 PRODUCT PORTFOLIO
26.9.5 RECENT DEVELOPMENTS
26.1 SYSMEX CORPORATION
26.10.1 COMPANY OVERVIEW
26.10.2 REVENUE ANALYSIS
26.10.3 GEOGRAPHIC PRESENCE
26.10.4 PRODUCT PORTFOLIO
26.10.5 RECENT DEVELOPMENTS
26.11 ZYTOMED SYSTEMS GMBH
26.11.1 COMPANY OVERVIEW
26.11.2 REVENUE ANALYSIS
26.11.3 GEOGRAPHIC PRESENCE
26.11.4 PRODUCT PORTFOLIO
26.11.5 RECENT DEVELOPMENTS
26.12 APPLIED SPECTRAL IMAGING
26.12.1 COMPANY OVERVIEW
26.12.2 REVENUE ANALYSIS
26.12.3 GEOGRAPHIC PRESENCE
26.12.4 PRODUCT PORTFOLIO
26.12.5 RECENT DEVELOPMENTS
26.13 ABBOTT
26.13.1 COMPANY OVERVIEW
26.13.2 REVENUE ANALYSIS
26.13.3 GEOGRAPHIC PRESENCE
26.13.4 PRODUCT PORTFOLIO
26.13.5 RECENT DEVELOPMENTS
26.14 THERMO FISHER SCIENTIFIC INC.
26.14.1 COMPANY OVERVIEW
26.14.2 REVENUE ANALYSIS
26.14.3 GEOGRAPHIC PRESENCE
26.14.4 PRODUCT PORTFOLIO
26.14.5 RECENT DEVELOPMENTS
26.15 BIODOT
26.15.1 COMPANY OVERVIEW
26.15.2 REVENUE ANALYSIS
26.15.3 GEOGRAPHIC PRESENCE
26.15.4 PRODUCT PORTFOLIO
26.15.5 RECENT DEVELOPMENTS
26.16 BIO-RAD LABORATORIES, INC.
26.16.1 COMPANY OVERVIEW
26.16.2 REVENUE ANALYSIS
26.16.3 GEOGRAPHIC PRESENCE
26.16.4 PRODUCT PORTFOLIO
26.16.5 RECENT DEVELOPMENTS
26.17 AGILENT TECHNOLOGY
26.17.1 COMPANY OVERVIEW
26.17.2 REVENUE ANALYSIS
26.17.3 GEOGRAPHIC PRESENCE
26.17.4 PRODUCT PORTFOLIO
26.17.5 RECENT DEVELOPMENTS
26.18 CYTOTEST INC
26.18.1 COMPANY OVERVIEW
26.18.2 REVENUE ANALYSIS
26.18.3 GEOGRAPHIC PRESENCE
26.18.4 PRODUCT PORTFOLIO
26.18.5 RECENT DEVELOPMENTS
26.19 ABNOVA CORPORATION
26.19.1 COMPANY OVERVIEW
26.19.2 REVENUE ANALYSIS
26.19.3 GEOGRAPHIC PRESENCE
26.19.4 PRODUCT PORTFOLIO
26.19.5 RECENT DEVELOPMENTS
26.2 BIOCARE MEDICAL, LLC
26.20.1 COMPANY OVERVIEW
26.20.2 REVENUE ANALYSIS
26.20.3 GEOGRAPHIC PRESENCE
26.20.4 PRODUCT PORTFOLIO
26.20.5 RECENT DEVELOPMENTS
26.21 GENEMED BIOTECHNOLOGIES, INC.
26.21.1 COMPANY OVERVIEW
26.21.2 REVENUE ANALYSIS
26.21.3 GEOGRAPHIC PRESENCE
26.21.4 PRODUCT PORTFOLIO
26.21.5 RECENT DEVELOPMENTS
27 RELATED REPORTS
28 CONCLUSION
29 QUESTIONNAIRE
30 ABOUT DATA BRIDGE MARKET RESEARCH
